Braidwell LP Purchases Shares of 1,620,377 Damora Therapeutics, Inc. Common Stock $DMRA

Braidwell LP purchased a new stake in Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,620,377 shares of the company’s stock, valued at approximately $42,146,000. Damora Therapeutics, Inc. Common Stock comprises 1.6% of Braidwell LP’s investment portfolio, making the stock its 21st biggest position. Braidwell LP owned approximately 2.62% of Damora Therapeutics, Inc. Common Stock at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Ikarian Capital LLC purchased a new stake in Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at approximately $6,574,000. Jain Global LLC purchased a new position in Damora Therapeutics, Inc. Common Stock during the fourth quarter worth $2,774,000. Remedium Capital Partners LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter worth $2,772,000. Boothbay Fund Management LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter worth $2,204,000. Finally, Connective Capital Management LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the third quarter valued at $100,000. 14.20% of the stock is owned by hedge funds and other institutional investors.

Damora Therapeutics, Inc. Common Stock Trading Up 0.1%

NASDAQ DMRA opened at $28.18 on Thursday. The business’s 50-day moving average price is $29.53 and its 200 day moving average price is $26.88. Damora Therapeutics, Inc. Common Stock has a twelve month low of $2.45 and a twelve month high of $38.33. The company has a market capitalization of $1.74 billion, a PE ratio of -8.36 and a beta of 1.46.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.06. Equities analysts predict that Damora Therapeutics, Inc. Common Stock will post -2.06 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on DMRA. Wedbush increased their price objective on Damora Therapeutics, Inc. Common Stock from $35.00 to $40.00 and gave the company an “outperform” rating in a research note on Thursday, July 30th. TD Cowen upgraded shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a report on Monday, August 24th. Jefferies Financial Group started coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, July 27th. They set a “buy” rating and a $50.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Thursday, June 18th. Finally, HC Wainwright reissued a “buy” rating and set a $45.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, July 21st. Three analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $44.00.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical?stage biotechnology company developing small?molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin?3, an extracellular carbohydrate?binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase?like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin?3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin?3 inhibitor being evaluated for systemic fibrotic disorders.